Order Total (1 Item Items):
Shipping Destination:
Rowinsky Eric (39 results)
Skip to main search results
Search filters
Product Type
- All Product Types
- Books (39)
- Magazines & Periodicals (No further results match this refinement)
- Comics (No further results match this refinement)
- Sheet Music (No further results match this refinement)
- Art, Prints & Posters (No further results match this refinement)
- Photographs (No further results match this refinement)
- Maps (No further results match this refinement)
- Manuscripts & Paper Collectibles (No further results match this refinement)
Condition Learn more
- New (28)
- As New, Fine or Near Fine (6)
- Very Good or Good (1)
- Fair or Poor (No further results match this refinement)
- As Described (4)
Binding
Collectible Attributes
- First Edition (1)
- Signed (No further results match this refinement)
- Dust Jacket (No further results match this refinement)
- Seller-Supplied Images (10)
- Not Print on Demand (27)
Language (1)
Free Shipping
Seller Location
Seller Rating
-
Paclitaxel in cancer treatment
Seller: Cotswold Internet Books, Cheltenham, United Kingdom
Seller rating 5 out of 5 stars
First Edition
Condition: Used - Very Good. VG hardback. 1st ed. A tidy copy in tight binding Used - Very Good. VG hardback.
-
Handbook of Anticancer Drug Development
Language: English
Published by Lippincott Williams & Wilkins, 2003
ISBN 10: 078174010X ISBN 13: 9780781740104
Seller: Phatpocket Limited, Waltham Abbey, HERTS, United Kingdom
Seller rating 5 out of 5 stars
Condition: Good. Your purchase helps support Sri Lankan Children's Charity 'The Rainbow Centre'. Ex-library, so some stamps and wear, but in good overall condition. Our donations to The Rainbow Centre have helped provide an education and a safe haven to hundreds of children who live in appalling conditions.
-
Handbook Of Anticancer Drug Development
Language: English
Published by Lippincott Williams & Wilkins, 2003
ISBN 10: 078174010X ISBN 13: 9780781740104
Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
-
Handbook Of Anticancer Drug Development
Language: English
Published by Lippincott Williams & Wilkins, 2003
ISBN 10: 078174010X ISBN 13: 9780781740104
Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
-
Paclitaxel in cancer treatment
Seller: Antiquariat Wortschatz, Markt Hartmannsdorf, Austria
Seller rating 5 out of 5 stars
Hardcover. Condition: Sehr gut. kA (illustrator). kA. Auflage. Anzahl Bände: 1 - Bd.Nr.: kA - Sprache: en - Einband: Leinen - Gewicht: 620 - Illust.: kA - Zustand: Sehr gut - neuwertig.
-
Handbook of Anticancer Drug Development
Language: English
Published by Lippincott Williams & Wilkins, 2003
ISBN 10: 078174010X ISBN 13: 9780781740104
Condition: Used.
-
Handbook of Anticancer Drug Development
Language: English
Published by Lippincott Williams & Wilkins, 2003
ISBN 10: 078174010X ISBN 13: 9780781740104
Condition: Used.
-
Handbook of Anticancer Drug Development
Language: English
Published by Lippincott Williams and Wilkins, 2003
ISBN 10: 078174010X ISBN 13: 9780781740104
hardcover. Condition: Sehr gut. 400 Seiten; 9780781740104.2 Gewicht in Gramm: 2.
-
Handbook Of Anticancer Drug Development
Language: English
Published by Lippincott Williams & Wilkins, 2003
ISBN 10: 078174010X ISBN 13: 9780781740104
Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
-
HANDBOOK OF ANTICANCER DRUG DEVELOPMENT
Language: English
Published by Lippincott Williams & Wilkins, 2003
ISBN 10: 078174010X ISBN 13: 9780781740104
Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
-
Handbook of Anticancer Drug Development
Language: English
Published by Lippincott Williams & Wilkins, 2003
ISBN 10: 078174010X ISBN 13: 9780781740104
Condition: Used.
-
Condition: New.
-
mTOR Inhibition for Cancer Therapy: Past, Present and Future
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Seller rating 5 out of 5 stars
£ 86.64
£ 11.98 shipping
Ships from United Kingdom to U.S.A.Quantity: Over 20 available
Add to basketCondition: New. In.
-
PF. Condition: New.
-
Mtor Inhibition for Cancer Therapy : Past, Present and Future
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: New.
-
Mtor Inhibition For Cancer Therapy: Past
Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Ireland
Seller rating 5 out of 5 stars
Condition: New.
-
Condition: New. pp. 308 Reprint edition NO-PA16APR2015-KAP.
-
Condition: New.
-
Taschenbuch. Condition: Neu. mTOR Inhibition for Cancer Therapy: Past, Present and Future | Monica Mita (u. a.) | Taschenbuch | vi | Englisch | 2016 | Springer | EAN 9782817805573 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
-
Condition: New. pp. 400.
-
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
-
Paperback. Condition: Brand New. reprint edition. 300 pages. French language. 9.25x6.10x0.70 inches. In Stock.
-
Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
-
Condition: Sehr gut. Zustand: Sehr gut | Seiten: 308 | Sprache: Englisch | Produktart: Bücher | This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
-
Mtor Inhibition for Cancer Therapy : Past, Present and Future
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
£ 157.99
£ 15 shipping
Ships from United Kingdom to U.S.A.Quantity: Over 20 available
Add to basketCondition: As New. Unread book in perfect condition.
-
Paperback. Condition: Like New. Like New. book.
-
Condition: As New. Unread book in perfect condition.
-
Condition: new. Questo è un articolo print on demand.
-
Condition: new. Questo è un articolo print on demand.
-
mTOR Inhibition for Cancer Therapy: Past, Present and Future
Language: English
Published by Springer Paris Aug 2016, 2016
ISBN 10: 2817805577 ISBN 13: 9782817805573
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation. 308 pp. Englisch.
